Latvia Country Drug Report 2019

Key statistics

Most recent estimates and data reported

  EU range
  Year Country data Min. Max.

 

Cannabis
Lifetime prevalence of use — schools (% , Source: ESPAD) 2015 16.6 6.51 36.79
Last year prevalence of use — young adults (%) 2015 10 1.8 21.8
Last year prevalence of drug use — all adults (%) 2015 4.2 0.9 11
All treatment entrants (%) 2017 24 1.03 62.98
First-time treatment entrants (%) 2017 36 2.3 74.36
Quantity of herbal cannabis seized (kg) 2017 42.8 11.98 94 378.74
Number of herbal cannabis seizures 2017 848 57 151 968
Quantity of cannabis resin seized (kg) 2017 202.2 0.16 334 919
Number of cannabis resin seizures 2017 36 8 157 346
Potency — herbal (% THC) (minimum and maximum values registered) n.a. n.a. 0 65.6
Potency — resin (% THC) (minimum and maximum values registered) n.a. n.a. 0 55
Price per gram — herbal (EUR) (minimum and maximum values registered) 2017 10 - 15 0.58 64.52
Price per gram — resin (EUR) (minimum and maximum values registered) 2017 12 - 15 0.15 35
Cocaine
Lifetime prevalence of use — schools (% , Source: ESPAD) 2015 2.29 0.85 4.85
Last year prevalence of use — young adults (%) 2015 1.2 0.1 4.7
Last year prevalence of drug use — all adults (%) 2015 0.5 0.1 2.7
All treatment entrants (%) 2017 0.5 0.14 39.2
First-time treatment entrants (%) 2017 0.7 0 41.81
Quantity of cocaine seized (kg) 2017 2.3 0.32 44 751.85
Number of cocaine seizures 2017 61 9 42 206
Purity (%) (minimum and maximum values registered) 2017 15 - 81 0 100
Price per gram (EUR) (minimum and maximum values registered) 2017 70 - 120 2.11 350
Amphetamines
Lifetime prevalence of use — schools (% , Source: ESPAD) 2015 2.95 0.84 6.46
Last year prevalence of use — young adults (%) 2015 0.7 0 3.9
Last year prevalence of drug use — all adults (%) 2015 0.3 0 1.8
All treatment entrants (%) 2017 17.5 0 49.61
First-time treatment entrants (%) 2017 22.9 0 52.83
Quantity of amphetamine seized (kg) 2017 8.8 0 1 669.42
Number of amphetamine seizures 2017 157 1 5 391
Purity — amphetamine (%) (minimum and maximum values registered) 2017 4 - 72 0.07 100
Price per gram — amphetamine (EUR) (minimum and maximum values registered) 2017 10 - 15 3 156.25
MDMA
Lifetime prevalence of use — schools (% , Source: ESPAD) 2015 2.71 0.54 5.17
Last year prevalence of use — young adults (%) 2015 0.8 0.2 7.1
Last year prevalence of drug use — all adults (%) 2015 0.3 0.1 3.3
All treatment entrants (%) 2017 0.4 0 2.31
First-time treatment entrants (%) 2017 0.2 0 2.85
Quantity of MDMA seized (tablets) 2017 3 660 159 8 606 765
Number of MDMA seizures 2017 169 13 6 663
Purity (MDMA mg per tablet) (minimum and maximum values registered) 2017 42 - 106 0 410
Purity (MDMA % per tablet) (minimum and maximum values registered) n.a. n.a. 2.14 87
Price per tablet (EUR) (minimum and maximum values registered) 2017 4 - 5 1 40
Opioids
High-risk opioid use (rate/1 000) 2017 5.68 0.48 8.42
All treatment entrants (%) 2017 49.4 3.99 93.45
First-time treatment entrants (%) 2017 28.7 1.8 87.36
Quantity of heroin seized (kg) 2017 0.2 0.01 17 385.18
Number of heroin seizures 2017 66 2 12 932
Purity — heroin (%) (minimum and maximum values registered) 2017 5 - 43 0 91
Price per gram — heroin (EUR) (minimum and maximum values registered) 2017 60 - 150 5 200
Newly diagnosed HIV cases related to injecting drug use (cases/million population, Source: ECDC) 2017 40 0 47.8
HIV prevalence among PWID* (%) 2017 7.7 0 31.1
HCV prevalence among PWID* (%) 2017 56.8 14.7 81.5
Injecting drug use (cases rate/1 000 population) 2016 6.07 0.08 10.02
Drug-induced deaths — all adults (cases/million population) 2017 17.48 2.44 129.79
Health and social responses
Syringes distributed through specialised programmes 2017 833 817 245 11 907 416
Clients in substitution treatment 2017 669 209 178 665
Treatment demand
All entrants 2017 811 179 118 342
First-time entrants 2017 431 48 37 577
All clients in treatment 2017 2 590 1 294 254 000
Drug law offences
Number of reports of offences 2017 5 173 739 389 229
Offences for use/possession n.a. n.a. 130 376 282

Latvia main page

Methodological note: Analysis of trends is based only on those countries providing sufficient data to describe changes over the period specified. The reader should also be aware that monitoring patterns and trends in a hidden and stigmatised behaviour like drug use is both practically and methodologically challenging. For this reason, multiple sources of data are used for the purposes of analysis in this report. Caution is therefore required in interpretation, in particular when countries are compared on any single measure. Detailed information on methodology and caveats and comments on the limitations in the information set available can be found in the EMCDDA Statistical Bulletin.